GSK and Genmab’s Ofatumumab Wins FDA Breakthrough Therapy Designation

The FDA has approved GSK and Genmab’a Arzerra (ofatumumab) in combination with chlorambucil as a breakthrough therapy for chronic lymphocytic leukemia.
Pharmaceutical Business Review